FDA committee to discuss Forest's COPD compound

FDA's Pulmonary-Allergy Drugs Advisory Committee will meet Feb. 23 to discuss an NDA from Forest Laboratories Inc. (NYSE:FRX) for aclidinium bromide to treat bronchospasm associated with chronic obstr...